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Abstract
Background: Patients’ beliefs about treatment influence treatment engagement and adherence. The Necessity-Concerns
Framework postulates that adherence is influenced by implicit judgements of personal need for the treatment (necessity
beliefs) and concerns about the potential adverse consequences of taking it.
Objective: To assess the utility of the NCF in explaining nonadherence to prescribed medicines.
Data sources: We searched EMBASE, Medline, PsycInfo, CDSR/DARE/CCT and CINAHL from January 1999 to April 2013 and
handsearched reference sections from relevant articles.
Study eligibility criteria: Studies using the Beliefs about Medicines Questionnaire (BMQ) to examine perceptions of
personal necessity for medication and concerns about potential adverse effects, in relation to a measure of adherence to
medication.
Participants: Patients with long-term conditions.
Study appraisal and synthesis methods: Systematic review and meta-analysis of methodological quality was assessed by
two independent reviewers. We pooled odds ratios for adherence using random effects models.
Results: We identified 3777 studies, of which 94 (N= 25,072) fulfilled the inclusion criteria. Across studies, higher adherence
was associated with stronger perceptions of necessity of treatment, OR = 1.742, 95% CI [1.569, 1.934], p,0.0001, and fewer
Concerns about treatment, OR= 0.504, 95% CI: [0.450, 0.564], p,0.0001. These relationships remained significant when data
were stratified by study size, the country in which the research was conducted and the type of adherence measure used.
Limitations: Few prospective longitudinal studies using objective adherence measures were identified.
Conclusions: The Necessity-Concerns Framework is a useful conceptual model for understanding patients’ perspectives on
prescribed medicines. Taking account of patients’ necessity beliefs and concerns could enhance the quality of prescribing
by helping clinicians to engage patients in treatment decisions and support optimal adherence to appropriate prescriptions.
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Introduction
Prescribing medicines is fundamental to the medical manage-
ment of most long-term conditions. However, approximately half
of this medication is not taken as directed, representing a failure to
translate potentially effective treatment into optimal outcomes for
patients and society [1,2]. Where prescriptions are appropriate,
this level of nonadherence has potentially serious consequences,
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both for individual patients, in terms of lost opportunities for
health gain with increased morbidity and mortality [3], and for the
health care system, in terms of wasted resources, increased use of
services and hospital admissions [4].
In the absence of a single definitive intervention to address
nonadherence [5], the NICE Medicines Adherence Guidelines
amalgamate insights from trials of interventions and explanatory
studies of nonadherence [1]. They apply a perceptions and
practicalities approach [4] recognising that nonadherence may be
both unintentional and intentional. Unintentional nonadherence
occurs when the patient wants to adhere but is unable to because
they lack capacity or resources. For example, they may not have
understood the instructions, cannot afford copayment costs, or
find it difficult to schedule, administer or remember the treatment.
Intentional nonadherence occurs when the patient decides not to
follow the recommendations. It is best understood in terms of the
perceptual factors (e.g. beliefs and preferences) influencing
motivation to start and continue with treatment.
Prescribing consultations do not occur in a vacuum. Patients
(and prescribers) bring pre-existing beliefs about the illness and
treatment [6,7] which influence the patient’s evaluation of the
prescription, their adherence and even beneficial [8] or adverse
outcomes [9]. Interventions to optimise adherence tend to be more
effective if they are tailored to the needs of the individual taking
account of the perceptions of the treatment as well as practical
abilities and resources that enable or impede their adherence [10].
Although the perceptual and practical dimensions of adherence
are influenced by the social, cultural, economic and healthcare
system contexts, taking account of the patient’s beliefs about the
prescribed medication is fundamental to shared-decision making
and supporting adherence [1,11].
Research conducted with patients with a variety of long-term
conditions suggests that the key beliefs influencing patients’ common-
sense evaluations of prescribed medicines can be grouped under two
categories: perceptions of personal need for treatment (Necessity
beliefs) and Concerns about a range of potential adverse consequenc-
es [7,12,13]. This ‘Necessity-Concerns Framework (NCF)’ potentially
offers a convenient model for clinicians to elicit and address key beliefs
underpinning patients’ attitudes and decisions about treatment.
Over the past decade, a number of studies have been
conducted, using a validated questionnaire, the Beliefs about
Medicines Questionnaire [14] to quantify Necessity beliefs and
Concerns in order to explore the relationship between these beliefs
and adherence. This research spans a range of long-term medical
conditions, across different settings and within various cultural
groups. Many of the individual studies have demonstrated the
utility of the NCF in explaining nonadherence to medication (e.g.
[15–18]). It is therefore timely that a meta-analysis is performed to
consolidate the results from these studies and to examine the
explanatory value of the NCF in predicting adherence to
medication prescribed for long-term medical conditions. In line
with the underlying theory, we hypothesized that adherence in
long-term conditions would be associated with stronger percep-
tions of Necessity for treatment and fewer Concerns about adverse
consequences.
Methods
This review was conducted in line with the MOOSE guidelines
for meta-analysis of observational trials [19].
Literature Search
A computerised literature search was conducted by the
investigators on April 22nd, 2013 using EMBASE, Medline,
PsycInfo, CDSR/DARE/CCT and CINAHL. The search strat-
egy included the following terms:
BMQ or belief$
and
treatment$ or medicine$ or medication$
and
adheren$ or complian$
The search was limited to studies published from the year 1999
onwards (the year in which the BMQ was published). Duplicates
were removed.
Inclusion and Exclusion Criteria
Identified studies were included in the meta-analysis if they met
the following criteria:
(1) participants were suffering from a long-term condition
(2) participants were taking medication
(3) participants were adults
(4) the article was published in a peer-reviewed journal
(5) the Necessity and/or Concerns subscales of the BMQ were
used
(6) a measure of adherence was employed
There were no restrictions based on language, or on cultural or
geographical factors.
Titles and abstracts were screened for relevance, and the full
text of relevant articles was obtained. Data from each article was
extracted as described below.
Selection of Results When Multiple Relationships
between Beliefs and Adherence Were Reported
Fifteen studies reported multiple associations of beliefs related to
different adherence measurements (details reported in Table 1).
Where the choice was between adherence measures, the most
objective measure was selected for the meta-analysis. Therefore,
electronic monitoring of adherence [20] and prescription redemp-
tion data [16] were chosen over self-report. Where data was
presented for both ‘on demand’ and prophylactic medications,
data for the prophylactic medication data were chosen [21,22], for
consistency with medications prescribed for other long-term
conditions. In studies where cross-sectional and longitudinal data
were both available, longitudinal data was used within the analysis
[21,23–26]. Where one group provided cross-sectional data at
multiple timepoints, the timepoint with the fewest missing data
points was selected [27]. If the choice was between two self report
measures of adherence, we used the more commonly used
measure. Thus the Morisky Medication Adherence Scale (MMAS)
was chosen over the Brief Medication Questionnaire [28] and the
ACTG adherence measure was used over the Walsh VAS scale
[29]. Where patients within a sample were taking multiple
medications and individual associations were provided for each
medication [30,31], the mean association was used within the
meta-analysis but individual effect sizes are reported in Table 1 to
facilitate comparison. Where data on two samples are reported
within the same study [32,33] we included both associations within
the analysis.
Data Extraction
The following information was extracted from papers onto
coding forms: author names, date of publication, the country in
which the research was conducted (dichotomized into UK or non-
UK), sample size, illness group, sex (% male), mean age, study
design (cross-sectional, longitudinal or prospective), the number of
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Necessity and Concerns items included (since items may be added
specific to the medication prescribed), the adherence measure
used, information (means and standard deviations, odds ratios and
95% confidence intervals or correlation coefficients) to calculate
the effect size between adherence and Necessity beliefs and
Concerns, and the p-value. Where the full required statistics were
not reported, authors were contacted for further information.
Methodology/Quality Assessment
A simple methodology assessment tool was devised for this
study. Methodology was assessed by two of three independent
expert raters (SC, RP and VC) using the following parameters:
– study location (UK or non-UK)
– study design (cross-sectional or longitudinal/prospective)
– measure of adherence (self-report or objective measure
[electronic monitors, prescription redemption, blood test
results]).
– sample size (,82 = 0 or $82 = 1). This was based on the
sample needed to detect a medium effect size for a correlation
(r= 0.3) with an alpha level of 0.05 and 80% power.
Ratings were completed independently and then combined.
There were no disagreements regarding ratings.
Statistical Analysis
The primary outcome measure was adherence to medication.
For each study, the effect size was expressed as an odds ratio with
95% confidence intervals. Where studies reported the standard
mean difference or correlation coefficient, the effect size was
converted into an odds ratio, using the Comprehensive Meta-
Analysis program. We used a random effects model to accommo-
date heterogeneity between studies which was anticipated due to
differences with respect to sample characteristics, study design and
the adherence measure used.
The presence of significant heterogeneity across studies was
examined using the chi-squared statistic (Q). The magnitude of this
heterogeneity across studies was estimated using the I2 statistic
Figure 1. Selection process for study inclusion.
doi:10.1371/journal.pone.0080633.g001
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[34], which assesses the percentage of variance among studies
which is not due to chance.
Sensitivity analyses were conducted to ascertain whether the
effect sizes seen were robust when individual studies, or studies
grouped based on the methodological factors described above
were excluded.
Orwin’s fail-safe N [35,36] was calculated to estimate the
number of unpublished studies necessary to reverse any conclusion
that a significant effect exists (based on the conservative
assumption that unpublished studies would have effect sizes of
equal magnitude but opposite direction to the overall effect size in
this meta-analysis). Egger’s t-test and funnel plots were also used to
test for publication bias, in line with recent recommendations [37].
Results
Selection of Studies
Ninety-four percent (3554) of the 3775 studies retrieved were
rejected after checking the titles and abstracts against the selection
criteria above (Figure 1). 223 relevant articles were identified. A
search of the reference lists of these articles revealed one further
relevant study [38].
Of the 223 studies identified, a further 129 were excluded
(Figure 1). Thirty of these were unpublished studies and
conference proceedings. These were investigated further and
authors were contacted where necessary to clarify whether
unpublished work had led to publications [39–45]. Sixteen studies
[44,46–59] [60] had since been published, fifteen of which already
formed part of the included list and one additional eligible study
was available online early [61]. Six papers reported data on
samples which overlapped with included studies [62–67], and four
were protocols for ongoing studies [68–71].
Thirteen studies were excluded because they did not include a
measure of medication adherence [72–85]. Two of these included
separate assessment modes for intentional and unintentional
adherence but no overall adherence assessment [80,85]. Fifty-five
studies did not use the BMQ Specific scales [86–140]. Four studies
were excluded because the relationship between treatment beliefs
and adherence behaviour was not reported [24,141–143]. Two
articles were conducted in acute rather than long-term condition
samples (influenza [144] and antibiotic use [145]) and one article
was excluded because parental beliefs about medicine were
measured [146]. Thirteen studies study met the inclusion criteria
but the article did not contain the required statistical information.
We contacted the authors but were unable to obtain the relevant
data [38,147–158]. Thus, once screened against the inclusion
criteria, 94 articles were retained for inclusion in the meta-analysis.
Table 1 provides a summary of each of the studies included in the
meta-analysis.
Three of the included studies [16,159,160] reported associations
between adherence and Necessity beliefs, but not Concerns. The
authors of these articles were contacted, but the data for Concerns
was unavailable. Two studies [32,33] reported two largely non-
overlapping samples for both Necessity beliefs and Concerns.
Thus, data for 91 studies and 93 comparisons for Concerns, and
data for 94 studies and 96 comparisons for Necessity beliefs, were
included in the meta-analysis.
Sample Characteristics
The mean age of participants in the 94 included studies ranged
from 24.0 to 74.2, with an overall mean age of 55.8 (it was not
possible to calculate the mean age in 13 studies). The percentage of
males ranged from 0–100% (breast cancer and haemophilia
samples respectively), with an overall percentage of males of
49.7% male (excluding 3 studies where it was not possible to
calculate the number of males). Sample sizes ranged from 16 to
1871.
The total sample, N= 25,072, encompassed patients with
asthma, renal disease, organ transplantation, dialysis chronic pain,
kidney transplantation, cancer, cardiovascular disorders, Marfan’s
syndrome, depression, haemophilia, diabetes, HIV, rheumatoid
arthritis, osteoporosis, thalassemia, inflammatory bowel disease,
bipolar disorder, schizophrenia, epilepsy, migraine, back prob-
lems, glaucoma and mixed chronic illness.
Thirty-three studies (35.1%) used the MARS to measure
adherence, 20 used the Morisky Medication Adherence Scale
(21.2%), 3 used pharmacy refill (3.2%), 3 used electronic
monitoring (3.2%) and two or fewer studies used the remaining
measures.
Effect Sizes
Necessity beliefs. There was a significant relationship
between Necessity beliefs and adherence, OR= 1.742, 95% CI
[1.569, 1.934], p,0.0001. There was significant heterogeneity
between the 96 comparisons from 94 studies, Q(95) = 422.662,
p,0.001, which was substantial in magnitude, I2 = 77.52%.
Figure 2 presents the individual effect-size estimates and shows
that the relationship between Necessity beliefs and adherence was
significant (p,0.05) for 49 (51.0%) of the included studies.
Sensitivity analyses revealed that the overall result was not affected
when any single finding was omitted.
Concerns. There was a significant relationship between
Concerns and adherence and fewer Concerns about adverse
effects, OR = 0.502, 95% CI: [0.450, 0.560], p,0.0001. There was
significant heterogeneity among the 93 comparisons from 91
studies, Q(92) = 481.84, p,0.001, suggesting that factors other
than chance accounted for a moderate-substantial amount of
variance, I2 = 80.91%.
Figure 3 presents the individual effect-size estimates and shows
that the relationship between concerns and adherence was
significant (p,0.05) for 53 (57.0%) of the included studies.
Sensitivity analyses revealed that the overall result did not change
when any single finding was omitted.
Stratification by Long-Term Condition and Measurement
See Tables 2 and 3 for OR stratified by different long-term
conditions and adherence measures. Two few studies reported
data on the majority of conditions and measures to allow statistical
tests for heterogeneity.
Methodology/Quality Assessment
See Table 4 for sensitivity analyses.
Study location. Most studies were conducted outside of the
UK (n = 62; 66.0%). Stronger effects were apparent for both
Necessity and Concerns for studies conducted in the UK relative
to studies conducted outside of the UK, however the relationship
between Necessity and Concerns was significant for both locations.
Substantial and significant heterogeneity was present in all
analyses.
Study design. The majority of studies (n = 77, 81.9%) were
cross-sectional, with few studies using longitudinal or prospective
designs (n = 17; 18.1%). Effect sizes were similar for longitudinal/
prospective and cross-sectional designs for both Necessity and
Concerns. Substanital and signficant heterogeneity was present in
all analyses.
Measurement of adherence. Eighty-three studies (88.3%)
employed measured adherence using self-report, while 11 (11.7%)
used other methods. The association between adherence and
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Figure 2. Forest plot of effect sizes for BMQ Necessity and medication adherence.
doi:10.1371/journal.pone.0080633.g002
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Figure 3. Forest plot of effect sizes for BMQ Concerns and medication adherence.
doi:10.1371/journal.pone.0080633.g003
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Concerns was smaller, but still significant, when objective
measures were used, and the heterogeneity around this estimate
was small. The association between Necessity beliefs and
adherence did not differ if objective or subjective adherence
measures were used. Heterogeneity around the subjective mea-
sures estimates and the objective Necessity estimate was substan-
tial.
Statistical power. Eighteen (19.1%) of the studies were
classed as having small samples (less than 82). The size of the
associations between Necessity and Concerns and adherence were
similar for smaller and larger studies. Heterogeneity estimates
indicated that variability around the larger samples estimates was
substantial. However, the smaller sample estimates were less
heterogeneous, with I2 values in the small range for Concerns and
the moderate range for Necessity beliefs.
Assessment of Risk of Publication Bias
Necessity. The fail-safe N (Nfs) was 96, indicating that there
would need to be$96 unpublished findings of an equal magnitude
but opposite direction, to reverse our conclusion that a significant
effect exists. Inspection of the funnel plot suggested asymmetry (see
Figure 4), however Duval and Tweedie’s trim and fill method did
not suggest that studies should be added/removed. Egger’s t-test
was significant, t(94) = 1.60, p,0.001, suggesting the presence of
asymmetry.
Concerns. The fail-safe N (Nfs) was 94, indicating that there
would need to be$94 unpublished findings of an equal magnitude
but opposite direction, to reverse our conclusion that a significant
effect exists. Funnel plot inspection suggested the presence of
asymmetry (see Figure 5), which was confirmed by a significant
Egger’s t-test, t(91) = 1.80, p,0.001. Further, Duval and Tweedie’s
trim and fill method suggested 13 studies should be added/
removed to make the funnel plot symmetrical. The location of the
imputed studies indicated that the asymmetry may arise from a
lack of reporting of studies which find a negative relationship
between concerns and adherence. However, the similarity
between the adjusted OR 0.567 95% CI [0.507, 0.634], which
includes the imputed trimmed and filled studies, and the observed
OR 0.504 95% CI [0.450, 0.564], suggests that any bias does not
have a large impact on the findings.
Table 2. Analyses Stratified By Long-Term Condition.
k OR (95% CI) p
Necessity
Asthma 7 2.610 1.802–3.780 ,0.001
Bipolar disorder 2 1.624 0.739–3.567 0.227
Blood disorders 3 1.512 0.580–3.944 0.398
Cancer 2 2.313 1.190–4.496 0.013
Depression 8 1.989 1.382–2.862 ,0.001
Diabetes 6 1.502 0.930–2.425 0.096
Dialysis/end stage renal disease 3 1.454 0.771–2.742 0.247
Epilepsy 2 0.859 0.284–2.602 0.789
Glaucoma 3 1.697 0.976–2.949 0.061
High cholesterol 2 1.497 0.659–3.401 0.335
HIV 9 1.742 1.242–2.444 0.001
Hypertension 7 1.426 0.980–2.075 0.064
IBD 3 1.775 1.560–2.020 ,0.001
Mixed sample 11 1.504 1.249–1.810 ,0.001
Organ transplant 5 2.875 1.561–5.294 0.001
Pain 2 1.239 0.468–3.280 0.666
Rheumatoid arthritis 5 3.277 1.106–9.708 0.032
Schizophrenia 2 3.301 1.115–9.777 0.031
Stroke/CHD/acute coronary syndrome 9 1.402 1.022–1.924 0.036
Concerns
Asthma 6 0.406 0.304–0.541 ,0.001
Bipolar disorder 2 0.410 0.250–0.672 ,0.001
Blood disorders 3 0.764 0.545–1.073 0.121
Cancer 2 0.771 0.411–1.445 0.417
Depression 8 0.408 0.215–0.772 0.006
Diabetes 6 0.450 0.202–1.003 0.051
Dialysis/end stage renal disease 3 0.509 0.211–1.232 0.134
Epilepsy 2 0.662 0.327–1.339 0.251
Glaucoma 3 0.909 0.258–3.204 0.882
High cholesterol 2 0.598 0.123–2.918 0.525
HIV 9 0.619 0.465–0.824 0.001
Hypertension 6 0.433 0.340–0.552 ,0.001
IBD 3 0.612 0.536–0.698 ,0.001
Mixed sample 11 0.423 0.339–0.501 ,0.001
Organ transplant 4 0.486 0.356–0.503 ,0.001
Pain 2 0.620 0.428–0.897 0.011
Rheumatoid arthritis 5 0.608 0.385–0.962 0.033
Schizophrenia 2 0.648 0.410–1.025 0.063
Stroke/CHD/acute coronary syndrome 9 0.518 0.382–0.704 ,0.001
Note. CHD= coronary heart disease.
doi:10.1371/journal.pone.0080633.t002
Table 3. Analyses Stratified by Adherence Measure.
k OR (95% CI) p
Necessity
Brief Medication Questionnaire 2 2.350 1.122–4.341 0.022
CQ-R 2 18.327 5.696–58.967 ,0.001
Electronic monitoring 3 1.625 0.599–4.412 0.340
MARS 33 1.838 1.581–2.137 ,0.001
MASRI 2 2.048 1.390–3.018 ,0.001
MMAS 20 1.558 1.305–1.862 ,0.001
Pharmacy refill 3 1.668 0.684–4.066 0.260
Concerns
Brief Medication Questionnaire 2 0.415 0.131–1.321 0.137
CQ-R 2 0.546 0.286–1.044 0.067
Electronic monitoring 3 0.620 0.403–0.946 0.027
MARS 31 0.425 0.362–0.500 ,0.001
MASRI 2 0.410 0.251–0.669 ,0.001
MMAS 20 0.590 0.426–0.817 0.002
Pharmacy refill 3 0.785 0.630–0.979 0.031
Note. CQ-R = Compliance Questionnaire- Rheumatology from de Klerk, van der
Heijde, Landewe´, van der Tempel, & van der Linden (2003), MARS=Medication
Adherence Report Scale Scale from Horne et al., (1999), MASRI =Medication
Adherence Self-Report Index from Walsh et al., 2002, MMAS=Morisky
Medication Adherence Scale from Morisky, Green, & Levine (1986).
doi:10.1371/journal.pone.0080633.t003
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Discussion
This meta-analytic review indicates that the Necessity-Concerns
Framework (NCF) is a potentially useful model for understanding
patients’ evaluations of prescribed medicines. The magnitude of
the aggregate effect sizes indicates that, for each standard
deviation increase in Necessity beliefs, the odds of adherence
increases by a factor of 1.7. Conversely, for each standard
deviation increase in Concerns, the odds of adherence decreases
by a factor of 2.0.
Strengths and Limitations of the Study
The sensitivity and publication bias analyses conducted confirm
our hypothesis that Necessity beliefs and Concerns are associated
with adherence/nonadherence to medicines, across a wide range
of conditions, medications, and study locations. No research
synthesis can transcend the limitations of the primary studies.
However, sensitivity analyses confirmed that this association is
robust across methodological features; remaining when small,
underpowered studies were removed, when only longitudinal/
prospective designs were included, and when self-report and non
self-report adherence assessments were included separately. The
majority of the studies relied solely on self-reported adherence.
Self-report measures have high face validity and high specificity for
nonadherence, however they may be subject to self-presentation
and recall bias [161]. Thus some people may be reporting higher
adherence rates than they actually attain. This bias does not
diminish our confidence in the finding that beliefs were related to
adherence, as there is no evidence that such a bias would be
associated with medication beliefs. Indeed some patients with high
Concerns and low Necessity beliefs may be expected to incorrectly
report high adherence in order to present themselves positively.
This pattern would attenuate the relationship found between
adherence and medication beliefs, making it less likely that we
would find an association between beliefs and adherence.
Moreover, given that this relationship remained when non-self
report measures were used, we are confident that the observed
relationships between beliefs and adherence are not an artifact
arising from the limitations of self-report. Only published studies
were included, creating a possible bias, since studies submitted for
publication may be more likely to have positive results and larger
effect sizes. Since for both Necessity beliefs and Concerns, the fail
safe N indicated that the number of additional negative findings
required to accept our null hypothesis was similar to the number of
studies included in this meta-analysis, and there was little
suggestion of publication bias through funnel plot analysis, our
findings appear to reflect a true relationship between beliefs and
adherence.
Stratifying by long-term condition and adherence measurement
revealed a need for further studies using objective measures, and
highlighted some conditions, for example epilepsy and functional
pain syndromes where further research is needed. We do not know
whether the Necessity-Concerns Framework will be of equal utility
across medications administered by different routes e.g. depot
Table 4. Analyses Stratified By Adherence Measure, Study Location, Design and Power.
k OR (95% CI) p I2 Heterogeneity test
Necessity
UK study 32 2.201 1.786–2.713 ,0.001 72.72%*** Q(1) = 7.67, p,0.05
Non-UK study 64 1.573 1.405–1.761 ,0.001 74.79%***
Concerns
UK study 31 0.403 0.335–0.485 ,0.001 62.75%*** Q(1) = 7.61, p,0.05
Non-UK study 62 0.555 0.486–0.635 ,0.001 82.48%***
Necessity
Subjective adherence measure 83 1.737 1.565–1.929 ,0.001 75.54%*** Q(1) = 0.031, p= 0.86
Objective adherence measure 13 1.817 1.114–2.963 0.017 86.20%***
Concerns
Subjective adherence measure 81 0.485 0.429–0.549 ,0.001 82.84%*** Q(1) = 13.55, p,0.001
Objective adherence measure 12 0.726 0.609–0.866 ,0.001 8.93%
Necessity
Prospective/longitudinal 18 1.526 1.243–1.874 ,0.001 63.02*** Q(1) = 1.82, p= 0.18
Cross-sectional 78 1.798 1.595–2.027 ,0.001 79.49%***
Concerns
Prospective/longitudinal 18 0.449 0.356–0.567 ,0.001 70.88%*** Q(1) = 1.14, p= 0.29
Cross-sectional 75 0.519 0.458–0.588 ,0.001 81.28%***
Necessity
Low power 18 1.848 1.290–2.646 0.001 46.19%* Q(1) = 0.12, p= 0.73
High power 78 1.730 1.550–1.930 ,0.001 80.16***
Concerns
Low power 17 0.488 0.371–0.643 ,0.001 0.00% Q(1) = 0.05, p= 0.82
High power 76 0.505 0.448–0.570 ,0.001 83.83%***
Note. *p,.05, ***p,.001 for Q statistic.
doi:10.1371/journal.pone.0080633.t004
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injections, or if practical barriers to care may be of relatively
greater importance in some groups using medications adminis-
tered through different routes.
Eighteen studies assessed whether Concerns and Necessity
beliefs could predict adherence using longitudinal/prospective
designs. The relationship was not reduced in these studies,
supporting the proposal that medication beliefs can influence
Figure 4. Funnel plot for BMQ Necessity and medication adherence.
doi:10.1371/journal.pone.0080633.g004
Figure 5. Funnel plot for BMQ Concerns and medication adherence.
doi:10.1371/journal.pone.0080633.g005
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later adherence as part of the self-regulation of illness [14]. We did
not restrict our inclusion criteria to studies published in English.
However, our search only identified one study published in any
other language, despite the fact that the BMQ was translated into
the native language for the study. Cultural values [162] can impact
on the way in which individuals interact with the healthcare
system. However, variations in treatment necessity and concerns
and association between these beliefs and adherence were noted
across different countries, languages and cultures. We found that
studies outside the UK, where the BMQ and it’s disease-specific
modifications have been predominantly developed, found reduced
associations between necessity and concerns beliefs and adherence.
Further work is needed to investigate potential cultural variations
in medication beliefs.
Implications for Research and Practice
The development of more effective methods for addressing
nonadherence is a priority for research and practice [1,5]. Our
findings suggest, that novel interventions to support informed
choice and optimal adherence to appropriately prescribed
medicines are likely to be more effective if they take account of
patients’ beleifs about the treatment and how they judge their
personal need for the prescription relative to concerns about
ponteial adfverse consequences of taking it. Necessity beliefs and
Concerns may trigger intentional nonadherence, for example, if
patients decide not to take their medication due to concerns
regarding potential or actual adverse consequences, and uninten-
tional nonadherence, (e.g. if patients who believe a medicine is not
important for their health forget to take it). Beliefs can have
counter-balancing effects on adherence, such as when patients
continue to take a medication they believe is essential for their
health despite concerns regarding adverse effects 15. The challenge
now is to develop effective interventions to address patients’ doubts
about the necessity for treatment and concerns about adverse
consequences in order to enhance adherence. The challenge goes
beyond ‘getting patients to take more medicines’. Our findings
show that many patients harbour significant, unresolved doubts
and concerns about prescribed treatment suggesting a fault-line
between patients’ and prescribers’ cultural perceptions of the
treatment. Viewed from the perspective of biomedicine, non-
adherence may seem irrational. However, from the patients’
perspective, nonadherence may be a ‘common-sense’ response to
their implicit appraisal of the treatment. For some patients
nonadherence might represent an informed choice. In this case the
outcome of ‘adherence support’ would be to avoid prescribing an
unwanted treatment, to the relief of patient and payer. However,
for others, evaluations of treatment necessity and concerns may be
based on misconceptions about the illness and treatment.
More detailed studies of patient representations illness and
treatment show that, even when treatment evaluations are based
on misconceptions they appear to draw on a ‘common-sense’ logic
[12,163,164]. For example, the need for daily medication may
seem less salient when symptoms are absent or cyclical [165–167].
Concerns about prescribed medication are not just related to side
effects but are common, even when the medication is well
tolerated. They are often related to beliefs about the negative
effects of medication and include worries about long-term effects,
dependence, cost of medication and dislike of having to rely on
medicines [14,167]. Concerns are related to more general beliefs
about pharmaceuticals as a class of treatment which are often
perceived as intrinsically harmful and over-prescribed by doctors
[167,168]. The package information leaflets, dispensed with many
prescription medicines may exacerbate concerns as they list all
possible side effects, leaving patients with outstanding questions
and making it difficult to understand the likely risk and place them
in context with potential benefits [169].
Nonadherence is often a hidden problem. Patients may be
reluctant to express doubts or concerns about prescribed
medication and to report nonadherence; sometimes because they
fear that this will be perceived by the prescriber as a lack of faith in
them. The first step to facilitating adherence is therefore to take a
‘no-blame approach’ and encourages an honest and open
discussion to identify nonadherence and the reasons for non-
adherence [1]. Adherence support should be tailored to the needs
of the individual addressing perceptions (e.g. necessity beliefs and
concerns) as well as practicalities (e.g. capacity and resources). This
can be approached in a three stage process: 1) communicating a
common-sense rationale for personal need that takes account of
the patient’s perceptions of the illness and symptoms expectations
and experiences 2) eliciting and addressing specific concerns and 3)
making the treatment as convenient and as easy to use a possible.
Interventions attempting to improve adherence by applying these
approaches have had encouraging results [142,170]. Nonadher-
ence remains a fault-line in clinical practice. Consideration of
patients’ perceptions of treatment necessity and concerns in
prescribing and treatment review is essential to support informed
choice and optimal adherence to appropriately prescribed
treatment.
Supporting Information
Supporting Information S1 PRISMA Checklist.
(DOC)
Acknowledgments
We would like to thank Christina Jackson for her help with the publication
bias analysis, and the authors who sent additional data for their assistance.
Author Contributions
Analyzed the data: VC RH RP SC AF NF. Wrote the paper: RH VC RP
SC. Conceived and designed the study: RH. Acquired the data: RP SC
VC. Critically revised the manuscript for important intellectual content:
RH SC RP NF AF VC.
References
1. National Institute for Health and Clinical Excellence (2009) Medicines
adherence: involving patients in decisions about prescribed medicines and
supporting adherence CG76. London: National Institute for Health and
Clinical Excellence.
2. World Health Organisation (2003) Adherence to Long-term Therapies:
Evidence for Action. Geneva: World Health Organisation.
3. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, et al. (2006)
A meta-analysis of the association between adherence to drug therapy and
mortality. BMJ 333: 15.
4. Horne R, Weinman J, Barber N, Elliott RA, Morgan M (2006) Concordance,
Adherence and Compliance in Medicine Taking: A conceptual map and
research priorities. London: National Institute for Health Research (NIHR)
Service Delivery and Organisation (SDO) Programme. Available: http://www.
sdo.lshtm.ac.uk/sdo762004.html. Accessed October 17th 2013.
5. Haynes RB, Yao X, Degani A, Kripalani S, Garg A, et al. (2005) Interventions
to enhance medication adherence. Cochrane Database Syst Rev: CD000011.
6. Weinman J, Petrie KJ, Moss-Morris R, Horne R (1996) The illness perception
questionnaire: A new method for assessing the cognitive representation of
illness. Psychology & Health 11: 431–445.
7. Horne R, Weinman J (1999) Patients’ beliefs about prescribed medicines and
their role in adherence to treatment in chronic physical illness - processes and
applications. Journal of Psychosomatic Research 47: 555–567.
8. Benedetti F, Carlino E, Pollo A (2011) How placebos change the patient’s
brain. Neuropsychopharmacology 36: 339–354.
Medication Adherence and Beliefs
PLOS ONE | www.plosone.org 19 December 2013 | Volume 8 | Issue 12 | e80633
9. Colloca L, Benedetti F (2007) Nocebo hyperalgesia: how anxiety is turned into
pain. Current Opinion in Anesthesiology 20: 435–439.
10. Horne R (2001) Compliance, adherence and concordance. In: Taylor K,
Harding G, editors. Pharmacy Practice. London: Taylor and Francis. 165–184.
11. De Maeseneer J, Roberts RG, Demarzo M, Heath I, Sewankambo N, et al.
(2012) Tackling NCDs: a different approach is needed. The Lancet 379: 1860–
1861.
12. Horne R (1997) Representations of medication and treatment: Advances in
theory and measurement In: Petrie KJ, Weinman JA, editors. Perceptions of
Health and Illness: Current Research and Applications. London: Harwood
Academic Press. 155–188.
13. Horne R (2003) Treatment perceptions and self regulation. In: Cameron LD,
Leventhal H, editors. The self-regulation of health and illness behaviour.
London: Routledge. 138–153.
14. Horne R, Weinman J, Hankins M (1999) The Beliefs about Medicines
Questionnaire: The development and evaluation of a new method for assessing
the cognitive representation of medication. Psychology and Health 14: 1–24.
15. Maidment R, Livingston G, Katona C (2002) Just keep taking the tablets:
adherence to antidepressant treatment in older people in primary care.
International Journal of Geriatric Psychiatry 17: 752–757.
16. Byer B, Myers LB (2000) Psychological correlates of adherence to medication
in asthma Psychology, Health and Medicine 5: 389–393.
17. Byrne M, Walsh J, Murphy AW (2005) Secondary prevention of coronary heart
disease: patient beliefs and health-related behaviour. Journal of Psychosomatic
Research 58: 403–415.
18. Clatworthy J, Bowskill R, Parham R, Rank T, Scott J, et al. (2009)
Understanding medication non-adherence in bipolar disorders using a
Necessity-Concerns Framework. Journal of Affective Disorders 116: 51–55.
19. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-
analysis of Observational Studies in Epidemiology. JAMA: The Journal of the
American Medical Association 283: 2008–2012.
20. Gonzalez J, Penedo F, Llabre M, Duran R, Antoni M, et al. (2007) Physical
symptoms, beliefs about medications, negative mood, and long-term HIV
medication adherence. Annals of Behavioural Medicine 34: 46–55.
21. de Thurah A, Norgaard M, Harder I, Stengaard-Pedersen K (2010)
Compliance with methotrexate treatment in patients with rheumatoid arthritis:
influence of patients’ beliefs about the medicine. A prospective cohort study.
Rheumatol Int 30: 1441–1448.
22. Llewellyn C, Miners A, Lee C, Harrington C, Weinman J (2003) The illness
perceptions and treatment beliefs of individuals with severe haemophilia and
their role in adherence to home treatment. Health Psychology 18: 185–2000.
23. French DP, Wade AN, Farmer AJ (2013) Predicting self-care behaviours of
patients with type 2 diabetes: The importance of beliefs about behaviour, not
just beliefs about illness. J Psychosom Res 74: 327–333.
24. Horne R, Clatworthy J, Hankins M, ASCOT Investigators (2010) High
adherence and concordance within a clinical trial of antihypertensives. Chronic
Illness 6: 243–251.
25. O’Carroll R, Whittaker J, Hamilton B, Johnston M, Sudlow C, et al. (2011)
Predictors of adherence to secondary preventive medication in stroke patients.
Ann Behav Med 41: 383–390.
26. Ovchinikova L, Smith L, Bosnic-Anticevich S (2011) Inhaler technique
maintenance: gaining an understanding from the patient’s perspective.
J Asthma 48: 616–624.
27. Unni EJ, Farris KB (2011) Unintentional non-adherence and belief in
medicines in older adults. Patient Educ Couns 83: 265–268.
28. Aikens JE, Nease DE Jr, Nau DP, Klinkman MS, Schwenk TL (2005)
Adherence to maintenance-phase antidepressant medication as a function of
patient beliefs about medication. Annals of Family Medicine 3: 23–30.
29. Johnson MO, Dilworth SE, Taylor JM, Darbes LA, Comfort ML, et al. (2012)
Primary relationships, HIV treatment adherence, and virologic control. AIDS
Behav 16: 1511–1521.
30. Batchelder AW, Gonzalez JS, Berg KM (2013) Differential medication
nonadherence and illness beliefs in co-morbid HIV and type 2 diabetes.
J Behav Med. doi: 10.1007/s10865-012-9486-1.
31. Allen LaPointe NM, Ou FS, Calvert SB, Melloni C, Stafford JA, et al. (2011)
Association between patient beliefs and medication adherence following
hospitalization for acute coronary syndrome. Am Heart J 161: 855–863.
32. Trachtenberg FL, Mednick L, Kwiatkowski JL, Neufeld EJ, Haines D, et al.
(2012) Beliefs about chelation among thalassemia patients. Health Qual Life
Outcomes 10: 148.
33. Unni E, Farris KB (2011) Determinants of different types of medication non-
adherence in cholesterol lowering and asthma maintenance medications: a
theoretical approach. Patient Educ Couns 83: 382–390.
34. Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of
Interventions: The Cochrane Collaboration. Available: http://handbook.
cochrane.org/. Accessed 2013 Nov 10.
35. Orwin R (1983) A Fail-Safe N for effect size in meta-analysis. Journal of
Educational Statistics 8: 157–159.
36. Rosenthal R (1979) The ‘‘file drawer problem’’ and tolerance for null results.
Psychological Bulletin 85: 638–641.
37. Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, et al. (2011)
Recommendations for examining and interpreting funnel plot asymmetry in
meta-analyses of randomised controlled trials. BMJ 343.
38. Magadza C, Radloff SE, Srinivas SC (2009) The effect of an educational
intervention on patients’ knowledge about hypertension, beliefs about
medicines, and adherence. Research in Social and Administrative Pharmacy
5: 363–375.
39. Aburuz SM, McElnay JC, Millership JS, Andrews WJ, Smyth S (2002) Factors
affecting self-care activities, postprandial plasma glucose, and HbA1c in
patients with type 2 diabetes. International Journal Of Pharmacy Practice 10S:
96.
40. Engova D, Duggan C, MacCallum P, Bates I (2004) The role of medication
adherence in warfarin anticoagulation control and its cognitive determinants.
British Journal of Haematology Supplement 1S: 57.
41. Engova D, Duggan C, MacCallum P, Bates I (2002) Patients’ understanding
and perceptions of treatment as determinants of adherence to warfarin
treatment. International Journal Of Pharmacy Practice 10S: R69.
42. Kendrew P, Ward F, Buick D, Wright D, Horne R (2001) Satisfaction with
information and its relationship with adherence in patients with chronic pain.
International Journal Of Pharmacy Practice 9S: R5.
43. Skingle SJ (2004) A study to investigate factors that may be associated with
patients’ decisions about starting disease modifying anti-rheumatic drugs.
Rheumatology 43S: 153.
44. Stafkey DR, Erickson SR, Kline-Rogers EM, Smith DE, Cooper JV, et al.
(2003) Relationship between patient beliefs about medication and self-reported
medication adherence six months after discharge for acute coronary
syndromes. Value in Health 6: 312.
45. Wade AN, Farmer AJ, French DP (2004) Association of beliefs about illness
and medication with self-care activities in noninsulin treated Type 2 diabetes.
Diabetic medicine Supplement 21S: 52.
46. Rajpura JR, Nayak R (2010) The role of illness burden and medication beliefs
in medication compliance of elderly with hypertension. Value in Health 3):
A168.
47. Batchelder A, Berg K, Carter A, Gonzalez J (2010) Differences in treatment
adherence, illness perceptions, and beliefs about medications in co-morbid HIV
and type 2 diabetes mellitus. Journal of the International Association of
Physicians in AIDS Care 9 (4): 253.
48. Chisholm-Burns M, Pinsky B, Parker G, Johnson P, Buzinec P, et al. (2010)
Patient reported factors influencing adherence to antirejection medications.
American Journal of Transplantation 10: 204.
49. Daleboudt GM, Broadbent E, McQueen F, Kaptein AA (2010) Intentional and
unintentional treatment non-adherence in patients with systemic lupus
erythematosus. Lupus 19: 167–168.
50. Gadkari A, McHorney C (2010) Prevalence and predictors of unintentional
nonadherence among adults with chronic disease who self-identify as being
adherent to prescription medications. Value in Health 3: A91.
51. McCann R, Jackson J, Stevenson M, Bickerstaff D, Cupples M, et al. (2010)
Medication management in older people with visual impairment. International
Journal of Pharmacy Practice 18: 95–96.
52. Moshkovska T, Mayberry J, Stone MA, Baker R, Bankart J, et al. (2010) The
benefit of a tailored patient preference intervention in adherence to 5- ASA
medication in ulcerative colitis: Results from a randomised controlled trial.
Gastroenterology 1: S518.
53. Weinberger MI, Mercado M, Sirey JA (2010) Medication beliefs and
adherence among community-dwelling older adults. American Journal of
Geriatric Psychiatry 1: S111.
54. Wilke T, Mueller S (2010) Why do patients not adhere to prescribed
medication regimes? Results of two German surveys. Value in Health 13 (7):
A380.
55. Wisnivesky JP, Roy A, Lurslurchachai L, Li X, Leventhal H, et al. (2010)
Complementary and alternative medication use and adherence to inhaled
corticosteroid among inner-city asthmatics. American Journal of Respiratory
and Critical Care Medicine Conference: American Thoracic Society
International Conference, ATS 181.
56. Clerisme-Beaty EM, Wise RA, Bartlett SJ, Rand CS (2010) Outcome
expectancy & medication adherence: ‘‘I think therefore I am’’. American
Journal of Respiratory and Critical Care Medicine Conference: American
Thoracic Society International Conference, ATS 181.
57. Foster JM, Smith L, Bosnic-Anticevich SZ, Usherwood T, Sawyer SM, et al.
(2010) The beliefs and behaviours which predict objectively measured
adherence to inhaled corticosteroids in asthma. American Journal of
Respiratory and Critical Care Medicine Conference: American Thoracic
Society International Conference, ATS 181.
58. Foster JM, Smith L, Bosnic-Anticevich SZ, Usherwood T, Sawyer SM, et al.
(2010) Adherence with inhaled corticosteroids in asthma is predicted by beliefs,
behaviours and side effects. Respirology 15: A29.
59. Harrold LR, Mazor KM, Peterson D, Firneno C, Yood RA (2010) Patient
knowledge and beliefs concerning gout and its treatment. Arthritis and
Rheumatism 62: 156.
60. Sud A, Kline-Rogers EM, Eagle KA, Fang J, Armstrong DF, et al. (2005)
Adherence to medications by patients after acute coronary syndromes. Annals
of Pharmacotherapy 39: 1792–1797.
61. Rajpura JR, Nayak R (2013) Role of Illness Perceptions and Medication Beliefs
on Medication Compliance of Elderly Hypertensive Cohorts. J Pharm Pract.
doi: 10.1177/0897190013493806.
62. Edmondson D, Horowitz CR, Goldfinger JZ, Fei K, Kronish IM (2013)
Concerns about medications mediate the association of posttraumatic stress
Medication Adherence and Beliefs
PLOS ONE | www.plosone.org 20 December 2013 | Volume 8 | Issue 12 | e80633
disorder with adherence to medication in stroke survivors. Br J Health Psychol.
In press.
63. Manze M, Rose AJ, Orner MB, Berlowitz DR, Kressin NR (2010)
Understanding racial disparities in treatment intensification for hypertension
management. J Gen Intern Med 25: 819–825.
64. Schuz B, Wurm S, Ziegelmann JP, Warner LM, Tesch-Romer C, et al. (2011)
Changes in functional health, changes in medication beliefs, and medication
adherence. Health Psychol 30: 31–39.
65. Shiyanbola OOFKB, Shiyanbola OOOSse (2010) Variation in patients’ and
pharmacists’ attribution of symptoms and the relationship to patients’ concern
beliefs in medications. Research in Social & Administrative Pharmacy Vol6(4),
Dec 2010, 334–344.
66. Horne R, Faasse K, Cooper V, Diefenbach MA, Leventhal H, et al. (2013) The
perceived sensitivity to medicines (PSM) scale: an evaluation of validity and
reliability. Br J Health Psychol 18: 18–30.
67. McHorney CA, Zhang NJ, Stump T, Zhao X (2012) Structural equation
modeling of the proximal-distal continuum of adherence drivers. Patient Prefer
Adherence 6: 789–804.
68. Lopez-Torres J, Parraga I, Del Campo JM, Villena A (2013) Follow up of
patients who start treatment with antidepressants: treatment satisfaction,
treatment compliance, efficacy and safety. BMC Psychiatry 13: 65.
69. O’Carroll R, Dennis M, Johnston M, Sudlow C (2010) Improving adherence to
medication in stroke survivors (IAMSS): a randomised controlled trial: study
protocol. BMC Neurol 10: 15.
70. Timmers L, Boons CC, Mangnus D, Moes JE, Swart EL, et al. (2011) The use
of erlotinib in daily practice: a study on adherence and patients’ experiences.
BMC Cancer 11: 284.
71. Timmers L, Swart EL, Boons CC, Mangnus D, van de Ven PM, et al. (2012)
The use of capecitabine in daily practice: a study on adherence and patients’
experiences. Patient Prefer Adherence 6: 741–748.
72. Gill A, de C. Williams AC (2001) Preliminary study of chronic pain patients’
concerns about cannabinoids as analgesics. Clinical Journal of Pain 17: 245–
248.
73. Hobro N, Weinman J, Hankins M (2004) Using the self-regulatory model to
cluster chronic pain patients: the first step towards identifying relevant
treatments? Pain 108: 276–283.
74. Horne R, Frost S, Hankins M, Wright S (2001) ‘In the eye of the beholder’:
Pharmacy students have more positive perceptions of medicines than students
of other disciplines. International Journal Of Pharmacy Practice 9: 85–89.
75. Horne R, Graupner L, Frost S, Weinman J, Wright SM, et al. (2004) Medicine
in a multi-cultural society: The effect of cultural background on beliefs about
medications. Social Science & Medicine 59: 1307–1313.
76. Jorgensen TM, Andersson KA, Mardby A-CM (2006) Beliefs about medicines
among Swedish pharmacy employees. Pharmacy World & Science 28: 233–
238.
77. Ramstrom H, Afandi S, Elofsson K, Petersson S (2006) Differences in beliefs
between patients and pharmaceutical specialists regarding medications. Patient
Education & Counselling 62: 244–249.
78. Gellaitry G, Cooper V, Davis C, Fisher M, Date HL, et al. (2006) Patients’
perception of information about HAART: impact on treatment decisions.
AIDS Care 17: 367–376.
79. Kumar K, Gordon C, Toescu V, Buckley CD, Horne R, et al. (2008) Beliefs
about medicines in patients with rheumatoid arthritis and systemic lupus
erythematosus: a comparison between patients of South Asian and White
British origin. Rheumatology 47: 690–697.
80. Wray J, Waters S, Radley-Smith R, Sensky T (2006) Adherence in adolescents
and young adults following heart or heart-lung transplantation. Pediatric
Transplantation 10: 694–700.
81. Aikens JE, Nease DE, Klinkman MS (2008) Explaining Patients’ Beliefs About
the Necessity and Harmfulness of Antidepressants. The Annals of Family
Medicine 6: 23–29.
82. Argentero P, Torchio E, Tibaldi G, Horne R, Clatworthy J, et al. (2010) The
beliefs about drug treatment. The Italian version of the BMQ (the Beliefs about
Medicines Questionnaire): its validity and applicability. [Italian] Le convizioni
sui trattamenti farmacologici. Validita e utilita della versione Italiana del BMQ
(the Beliefs about Medicines Questionnaire). Epidemiologia e psichiatria sociale
19: 86–92.
83. Allen LaPointe NM, Ou FS, Calvert SB, Melloni C, Stafford JA, et al. (2010)
Changes in beliefs about medications during long-term care for ischemic heart
disease. Am Heart J 159: 561–569.
84. Tempier R, Hepp SL, Duncan C, Rohr B, Hachey K, et al. (2010) Patient-
centered care in affective, non-affective, and schizoaffective groups: Patients’
opinions and attitudes. Community Mental Health Journal 46: 452–460.
85. Gadkari AS, McHorney CA (2012) Unintentional non-adherence to chronic
prescription medications: how unintentional is it really? BMC Health Serv Res
12: 98.
86. Burra TA, Chen E, McIntyre RS, Grace SL, Blackmore ER, et al. (2007)
Predictors of Self-Reported Antidepressant Adherence. Behavioral Medicine
32: 127–134.
87. Le TT, Bilderback A, Bender B, Wamboldt FS, Turner CF, et al. (2008) Do
asthma medication beliefs mediate the relationship between minority status and
adherence to therapy? J Asthma 45: 33–37.
88. Mann D, Allegrante J, Natarajan S, Halm E, Charlson M (2007) Predictors of
Adherence to Statins for Primary Prevention. Cardiovascular Drugs and
Therapy 21: 311–316.
89. McHorney CA, Schousboe JT, Cline RR, Weiss TW (2007) The impact of
osteoporosis medication beliefs and side-effect experiences on non-adherence to
oral bisphosphonates*. Current Medical Research and Opinion 23: 3137–
3152.
90. Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, et al. (2006)
Predictors of antipsychotic medication adherence in patients recovering from a
first psychotic episode. Schizophrenia Research 83: 53–63.
91. Scho¨nnesson LN, Williams ML, Ross MW, Diamond PM, Keel B (2007) Three
types of adherence to HIV antiretroviral therapy and their association with
AIDS diagnosis, medication side-effects, beliefs about antiretroviral therapy,
and beliefs about HIV disease. International Journal of STD & AIDS 18: 369–
373.
92. Talbot JT, Viall A, Direny A, de Rochars MB, Addiss D, et al. (2008)
Predictors of Compliance in Mass Drug Administration for the Treatment and
Prevention of Lymphatic Filariasis in Leogane, Haiti. The American Journal of
Tropical Medicine and Hygiene 78: 283–288.
93. van der Wal MHL, Jaarsma T, Moser DK, Veeger NJGM, van Gilst WH, et
al. (2006) Compliance in heart failure patients: the importance of knowledge
and beliefs. European Heart Journal 27: 434–440.
94. Wang X, Wu Z (2007) Factors associated with adherence to antiretroviral
therapy among HIV/AIDS patients in rural China. AIDS 21: S149–S155.
95. Wetzels G, Nelemans P, van Wijk B, Broers N, Schouten J, et al. (2006)
Determinants of poor adherence in hypertensive patients: Development and
validation of the ‘‘Maastricht Utrecht Adherence in Hypertension (MUAH)-
questionnaire’’. Patient Education and Counseling 64: 151–158.
96. Adepu R, Ari SM (2010) Influence of structured patient education on
therapeutic outcomes in diabetes and hypertensive patients. Asian Journal of
Pharmaceutical and Clinical Research 3: 174–178.
97. Gabriel AVC, Gabriel Aguc, Violato Cvuc (2010) Knowledge of and attitudes
towards depression and adherence to treatment: The Antidepressant
Adherence Scale (AAS). Journal of Affective Disorders Vol126(3), Nov 2010,
388–394.
98. Garay-Sevilla ME, Porras JS, Malacara JM (2011) Coping strategies and
adherence to treatment in patients with type 2 diabetes mellitus. Rev Invest
Clin 63: 155–161.
99. Garcia Vega OA, Buendia Rodriguez JA (2010) Beliefs about antihypertensive
medications in primary care patients: Validation of beliefs about medicines
questionnaire (BMQ) in Colombia. Value in Health 3: A177.
100. McCann RM, Jackson AJ, Stevenson M, Dempster M, McElnay JC, et al.
(2012) Help needed in medication self-management for people with visual
impairment: case-control study. Br J Gen Pract 62: e530–537.
101. McHorney CA, Gadkari AS (2010) Individual patients hold different beliefs to
prescription medications to which they persist vs nonpersist and persist vs
nonfulfill. Patient Prefer Adherence 4: 187–195.
102. Quintero MA, Quintero Mamjec (2010) Dimensions of treatment adherence
among Colombian women living with HIV/AIDS: A social perspective.
Revista Latinoamericana de Psicologia 42(2).
103. Anuradha S, Joshi A, Negi M, Nischal N, Rajeshwari K, et al. (2012) Factors
Influencing Adherence to ART: New Insights from a Center Providing Free
ART under the National Program in Delhi, India. J Int Assoc Physicians AIDS
Care (Chic).
104. Armour CL, Lemay K, Saini B, Reddel HK, Bosnic-Anticevich SZ, et al.
(2011) Using the community pharmacy to identify patients at risk of poor
asthma control and factors which contribute to this poor control. J Asthma 48:
914–922.
105. de Guzman AB, Guevara KIJ, Guiang FJB, Gutierrez ALI, Habaluyas AS, et
al. (2013) Developing a Model of Medication Adherence among Filipino
Elderly. Educational Gerontology 39: 298–313.
106. Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, et al. (2010) Patient-
reported reasons for discontinuing overactive bladder medication. BJU Int 105:
1276–1282.
107. Bermingham M, Hayden J, Dawkins I, Miwa S, Gibson D, et al. (2011)
Prospective analysis of LDL-C goal achievement and self-reported medication
adherence among statin users in primary care. Clin Ther 33: 1180–1189.
108. Brandt S, Dickinson B (2013) Time and risk preferences and the use of asthma
controller medication. Pediatrics 131: e1204–1210.
109. Brask-Lindemann D, Cadarette SM, Eskildsen P, Abrahamsen B (2011)
Osteoporosis pharmacotherapy following bone densitometry: importance of
patient beliefs and understanding of DXA results. Osteoporos Int 22: 1493–
1501.
110. Broadbent E, Donkin L, Stroh JC (2011) Illness and treatment perceptions are
associated with adherence to medications, diet, and exercise in diabetic
patients. Diabetes Care 34: 338–340.
111. Brubaker L, Fanning K, Goldberg EL, Benner JS, Trocio JN, et al. (2010)
Predictors of discontinuing overactive bladder medications. BJU Int 105: 1283–
1290.
112. Cottrell WN, Denaro CP, Emmerton L (2013) Exploring beliefs about heart
failure treatment in adherent and nonadherent patients: use of the repertory
grid technique. Patient Prefer Adherence 7: 141–150.
Medication Adherence and Beliefs
PLOS ONE | www.plosone.org 21 December 2013 | Volume 8 | Issue 12 | e80633
113. Crowley MJ, Grubber JM, Olsen MK, Bosworth HB (2013) Factors associated
with non-adherence to three hypertension self-management behaviors:
preliminary data for a new instrument. J Gen Intern Med 28: 99–106.
114. Davis DP, Jandrisevits MD, Iles S, Weber TR, Gallo LC (2012) Demographic,
socioeconomic, and psychological factors related to medication non-adherence
among emergency department patients. J Emerg Med 43: 773–785.
115. Ferreira C, Gay M, Regnier-Aeberhard F, Bricaire F (2010) Representation of
illness and of treatment side effects as determinants of adherence to treatment
of HIV patients. Annales Medico-Psychologiques 168: 25–33.
116. Foster JM, Smith L, Bosnic-Anticevich SZ, Usherwood T, Sawyer SM, et al.
(2012) Identifying patient-specific beliefs and behaviours for conversations
about adherence in asthma. Intern Med J 42: e136–144.
117. Garvie PA, Flynn PM, Belzer M, Britto P, Hu C, et al. (2011) Psychological
factors, beliefs about medication, and adherence of youth with human
immunodeficiency virus in a multisite directly observed therapy pilot study.
J Adolesc Health 48: 637–640.
118. Gerber BS, Cano AI, Caceres ML, Smith DE, Wilken LA, et al. (2010) A
pharmacist and health promoter team to improve medication adherence
among Latinos with diabetes. Ann Pharmacother 44: 70–79.
119. Jarab AS, Alqudah SG, Khdour M, Shamssain M, Mukattash TL (2012)
Impact of pharmaceutical care on health outcomes in patients with COPD.
Int J Clin Pharm 34: 53–62.
120. Joseph HA, Flores SA, Parsons JT, Purcell DW (2010) Beliefs about
transmission risk and vulnerability, treatment adherence, and sexual risk
behavior among a sample of HIV-positive men who have sex with men. AIDS
Care 22: 29–39.
121. Kalichman SC, Eaton L, Cherry C (2010) ‘There is no proof that HIV causes
AIDS’: AIDS denialism beliefs among people living with HIV/AIDS. Journal
of Behavioral Medicine 33: 432–440.
122. Kalichman SC, Amaral CM, White D, Swetsze C, Kalichman MO, et al.
(2012) Alcohol and adherence to antiretroviral medications: interactive toxicity
beliefs among people living with HIV. J Assoc Nurses AIDS Care 23: 511–520.
123. Kalichman SC, Grebler T, Amaral CM, McNerey M, White D, et al. (2013)
Intentional non-adherence to medications among HIV positive alcohol
drinkers: prospective study of interactive toxicity beliefs. J Gen Intern Med
28: 399–405.
124. Markotic F, Cerni Obrdalj E, Zalihic A, Pehar R, Hadziosmanovic Z, et al.
(2013) Adherence to pharmacological treatment of chronic nonmalignant pain
in individuals aged 65 and older. Pain Med 14: 247–256.
125. Natarajan N, Putnam W, Van Aarsen K, Beverley Lawson K, Burge F (2013)
Adherence to antihypertensive medications among family practice patients with
diabetes mellitus and hypertension. Can Fam Physician 59: e93–e100.
126. Ng CH, Smith DJ, King J, Ong S, Schweitzer I (2012) Medication attitudes
and beliefs in patients with psychotic and affective disorders on maintenance
treatment. Hum Psychopharmacol 27: 57–62.
127. Nordmann JP, Baudouin C, Renard JP, Denis P, Regnault A, et al. (2010)
Identification of noncompliant glaucoma patients using Bayesian networks and
the Eye-Drop Satisfaction Questionnaire. Clin Ophthalmol 4: 1489–1496.
128. Petrie KJ, Perry K, Broadbent E, Weinman J (2012) A text message
programme designed to modify patients’ illness and treatment beliefs improves
self-reported adherence to asthma preventer medication. Br J Health Psychol
17: 74–84.
129. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM (2012) Factors
associated with injection omission/non-adherence in the Global Attitudes of
Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab 9999.
130. Piette JD, Heisler M, Harand A, Juip M (2010) Beliefs about prescription
medications among patients with diabetes: variation across racial groups and
influences on cost-related medication underuse. J Health Care Poor
Underserved 21: 349–361.
131. Piette JD, Beard A, Rosland AM, McHorney CA (2011) Beliefs that influence
cost-related medication non-adherence among the ‘‘haves’’ and ‘‘have nots’’
with chronic diseases. Patient Prefer Adherence 5: 389–396.
132. Powers BJ, Danus S, Grubber JM, Olsen MK, Oddone EZ, et al. (2011) The
effectiveness of personalized coronary heart disease and stroke risk commu-
nication. Am Heart J 161: 673–680.
133. Saks EK, Wiebe DJ, Cory LA, Sammel MD, Arya LA (2012) Beliefs about
medications as a predictor of treatment adherence in women with urinary
incontinence. J Womens Health (Larchmt) 21: 440–446.
134. Shams MEE, Barakat EAME (2010) Measuring the rate of therapeutic
adherence among outpatients with T2DM in Egypt. Saudi Pharmaceutical
Journal 18: 225–232.
135. van Geffen EC, Heerdink ER, Hugtenburg JG, Siero FW, Egberts AC, et al.
(2010) Patients’ perceptions and illness severity at start of antidepressant
treatment in general practice. Int J Pharm Pract 18: 217–225.
136. Wilke T, Muller S, Morisky DE (2011) Toward identifying the causes and
combinations of causes increasing the risks of nonadherence to medical
regimens: combined results of two German self-report surveys. Value Health
14: 1092–1100.
137. Zarani F, Besharat MA, Sadeghian S, Sarami G (2010) The effectiveness of the
information-motivation-behavioral skills model in promoting adherence in
CABG patients. Journal of Health Psychology 15: 828–837.
138. Zeber JE, Miller AL, Copeland LA, McCarthy JF, Zivin K, et al. (2011)
Medication adherence, ethnicity, and the influence of multiple psychosocial
and financial barriers. Adm Policy Ment Health 38: 86–95.
139. Mardby A-C, Akerlind I, Jorgensen T (2007) Beliefs about medicines and self-
reported adherence among pharmacy clients. Patient Education & Counseling
69: 158–164.
140. Webb DG, Horne R, Pinching AJ (2001) Treatment-related empowerment:
preliminary evaluation of a new measure in patients with advanced HIV
disease. International Journal of STD & AIDS 12: 103–107.
141. Higgins N, Livingstone G, Katona C (2004) Concordance therapy: an
intervention to help older people take antidepressants. Journal of Affective
Disorders 81: 287–291.
142. Clifford S, Barber N, Elliott R, Hartley E, Horne R (2006) Patient-centred
advice is effective in improving adherence to medicines. Pharmacy World &
Science 28: 165–170.
143. Theunissen NC, de Ridder DT, Bensing JM, Rutten GE (2003) Manipulation
of patient-provider interaction: discussing illness representations or action plans
concerning adherence. Patient Education and Counselling 51: 247–258.
144. Bekker HL, Gough D, Williams M (2003) Attendance choices about the
Influenza Immunization Programme: evidence for targeting patients’ beliefs.
Psychology, Health and Medicine 8: 279–288.
145. Lam F, Stevenson FA, Britten N, Stell IM (2001) Adherence to antibiotics
prescribed in an accident and emergency department: the influnce of
consultation factors. European Journal of Emergency Medicine 8: 181–188.
146. Conn KM, Halterman JS, Fisher SG, Yoos HL, Chin NP, et al. (2005) Parental
beliefs about medications and medication adherence among urban children
with asthma. Ambulatory Pediatrics 5: 306–310.
147. Bane C, Hughes CM, McElnay JC (2006) The impact of depressive symptoms
and psychosocial factors on medication adherence in cardiovascular disease.
Patient Education & Counseling 60: 187–193.
148. Beck EM, Vo¨gelin R, Wirtz M, Cavelti M, Kvrgic S, et al. (2012) Do patients
with schizophrenia distinguish between attitudes toward antipsychotic medi-
cation and pharmacotherapy in general?: validation of the beliefs about
medication questionnaire. Journal of Nervous & Mental Disease 200: 33–43.
149. Bender BG, Apter A, Bogen DK, Dickinson P, Fisher L, et al. (2010) Test of an
interactive voice response intervention to improve adherence to controller
medications in adults with asthma. J Am Board Fam Med 23: 159–165.
150. Daleboudt GM, Broadbent E, McQueen F, Kaptein AA (2011) Intentional and
unintentional treatment nonadherence in patients with systemic lupus
erythematosus. Arthritis Care Res (Hoboken) 63: 342–350.
151. Gray TA, Fenerty C, Harper R, Spencer AF, Campbell M, et al. (2012)
Individualised patient care as an adjunct to standard care for promoting
adherence to ocular hypotensive therapy: an exploratory randomised
controlled trial. Eye (Lond) 26: 407–417.
152. Lennerling A, Forsberg A (2012) Self-reported non-adherence and beliefs about
medication in a Swedish kidney transplant population. Open Nurs J 6: 41–46.
153. Mann DM, Ponieman D, Montori VM, Arciniega J, McGinn T (2010) The
Statin Choice decision aid in primary care: a randomized trial. Patient Educ
Couns 80: 138–140.
154. Montgomery AT, Kalvemark Sporrong S, Manap N, Tully MP, Lindblad AK
(2010) Receiving a pharmaceutical care service compared to receiving standard
pharmacy service in Sweden-How do patients differ with regard to perceptions
of medicine use and the pharmacy encounter? Research in Social and
Administrative Pharmacy 6: 185–195.
155. Moshkovska T, Stone MA, Smith RM, Bankart J, Baker R, et al. (2011) Impact
of a tailored patient preference intervention in adherence to 5-aminosalicylic
acid medication in ulcerative colitis: results from an exploratory randomized
controlled trial. Inflamm Bowel Dis 17: 1874–1881.
156. Roy A, Lurslurchachai L, Halm EA, Li XM, Leventhal H, et al. (2010) Use of
herbal remedies and adherence to inhaled corticosteroids among inner-city
asthmatic patients. Ann Allergy Asthma Immunol 104: 132–138.
157. Shiyanbola OO, Farris KB, Chrischilles E (2012) Concern beliefs in
medications: Changes over time and medication use factors related to a
change in beliefs. Res Social Adm Pharm 9(4): 446–457.
158. van den Bemt BJ, den Broeder AA, van den Hoogen FH, Benraad B, Hekster
YA, et al. (2011) Making the rheumatologist aware of patients’ non-adherence
does not improve medication adherence in patients with rheumatoid arthritis.
Scand J Rheumatol 40: 192–196.
159. Ross S, Walker A, MacLeod MJ (2004) Patient compliance in hypertension:
role of illness perceptions and treatment beliefs. Journal of Human
Hypertension 18: 607–613.
160. Brown JL, Littlewood RA, Vanable PA (2013) Social-cognitive correlates of
antiretroviral therapy adherence among HIV-infected individuals receiving
infectious disease care in a medium-sized northeastern US city. AIDS Care
25(9): 1149–1158.
161. Garfield S, Clifford S, Eliasson L, Barber N, Willson A (2011) Suitability of
measures of self-reported medication adherence for routine clinical use: A
systematic review. BMC Medical Research Methodology 11: 149.
162. Hofstede G (2001) Culture’s Consequences, Comparing Values, Behaviors,
Institutions, and Organizations Across Nations. Thousand Oaks CA: Sage
Publications.
163. Leventhal H, Brissette I, Leventhal E (2003 ) The common-sense model of self-
regulation of health and illness. In: Cameron LD, Leventhal H, editors. The
self-regulation of health and illness behaviour. New York: Routledge. p.42.
164. Kleinman A (1986) Illness meanings and illness behaviour. In: McHugh S,
Vallis TM, editors. Illness behavior: A multidisciplinary model. New York:
Plenum Press. 149–160.
Medication Adherence and Beliefs
PLOS ONE | www.plosone.org 22 December 2013 | Volume 8 | Issue 12 | e80633
165. Halm EA, Mora P, Leventhal H (2006) No Symptoms, No Asthma*The Acute
Episodic Disease Belief Is Associated With Poor Self-Management Among
Inner-City Adults With Persistent Asthma. CHEST Journal 129: 573–580.
166. Horne R, Weinman J (2002) Self regulation and self management in asthma:
Exploring the role of illness perceptions and treatment beliefs in explaining
non-adherence to preventer medication. Psychology and Health 17: 17–32.
167. Horne R, Parham R, Driscoll R, Robinson A (2009) Patients’ attitudes to
medicines and adherence to maintenance treatment in inflammatory bowel
disease. Inflammatory Bowel Diseases 15: 837–844.
168. Calnan M, Montaner D, Horne R (2005) How acceptable are innovative
health-care technologies? A survey of public beliefs and attitudes in England
and Wales. Social Science & Medicine 60: 1937–1948.
169. Bowskill R, Clatworthy J, Parham R, Rank T, Horne R (2007) Patients’
perceptions of information received about medication prescribed for bipolar
disorder: Implications for informed choice. Journal of Affective Disorders 100:
253–257.
170. Elliott R, Barber N, Clifford S, Horne R, Hartley E (2008) The cost
effectiveness of a telephone-based pharmacy advisory service to improve
adherence to newly prescribed medicines. Pharmacy World & Science 30: 17–
23.
171. Aakre JM, Medoff DR, Dixon LB, Kreyenbuhl JA (2012) Beliefs about
antipsychotic versus hypoglycemic medications among individuals with serious
mental illness and type 2 diabetes. Patient Prefer Adherence 6: 389–394.
172. Aflakseir A (2012) Role of illness and medication perceptions on adherence to
medication in a group of Iranian patients with type 2 diabetes. J Diabetes 4:
243–247.
173. Aikens JE, Piette JD (2009) Diabetic Patients’ Medication Underuse, Illness
Outcomes, and Beliefs About Antihyperglycemic and Antihypertensive
Treatments. Diabetes Care 32: 19–24.
174. Aikens JE, Klinkman MS (2012) Changes in patients’ beliefs about their
antidepressant during the acute phase of depression treatment. Gen Hosp
Psychiatry 34: 221–226.
175. Barnes L, Moss-Morris R, Kaufusi M (2004) Illness beliefs and adherence in
diabetes mellitus: a comparison between Tongan and European patients. New
Zealand Medical Journal 117: 743.
176. Beck EM, Cavelti M, Kvrgic S, Kleim B, Vauth R (2011) Are we addressing
the ‘right stuff’ to enhance adherence in schizophrenia? Understanding the role
of insight and attitudes towards medication. Schizophr Res 132: 42–49.
177. Berglund E, Lytsy P, Westerling R (2013) Adherence to and beliefs in lipid-
lowering medical treatments: a structural equation modeling approach
including the necessity-concern framework. Patient Educ Couns 91: 105–112.
178. Bhattacharya D, Easthall C, Willoughby KA, Small M, Watson S (2012)
Capecitabine non-adherence: exploration of magnitude, nature and contrib-
uting factors. J Oncol Pharm Pract 18: 333–342.
179. Brown C, Battista DR, Bruehlman R, Sereika SS, Thase ME, et al. (2005)
Beliefs about antidepressant medications in primary care patients: relationship
to self-reported adherence. Medical Care 43: 1203–1207.
180. Butler JA, Peveler RC, Roderick P, Smith PWF, Horne R, et al. (2004)
Modifiable risk factors for non-adherence to immunosuppressants in renal
transplant recipients: A cross sectional study. Nephrology Dialysis Transplan-
tation 19: 3144–3149.
181. Chisholm-Burns M, Pinsky B, Parker G, Johnson P, Arcona S, et al. (2012)
Factors related to immunosuppressant medication adherence in renal
transplant recipients. Clin Transplant 26: 706–713.
182. Cooper V, Moyle GJ, Fisher M, Reilly G, Ewan J, et al. (2011) Beliefs about
antiretroviral therapy, treatment adherence and quality of life in a 48-week
randomised study of continuation of zidovudine/lamivudine or switch to
tenofovir DF/emtricitabine, each with efavirenz. AIDS Care 23: 705–713.
183. de Boer-van der Kolk IM, Sprangers MAG, Ende Mvd, Schreij G, Wolf Fd, et
al. (2008) Lower Perceived Necessity of HAART Predicts Lower Treatment
Adherence and Worse Virological Response in the ATHENA Cohort. JAIDS
Journal of Acquired Immune Deficiency Syndromes 49: 460–462.
184. De Las Cuevas C, Penate W, Sanz EJ (2013) Psychiatric outpatients’ self-
reported adherence versus psychiatrists’ impressions on adherence in affective
disorders. Hum Psychopharmacol 28: 142–150.
185. De Smedt RH, Jaarsma T, Ranchor AV, van der Meer K, Groenier KH, et al.
(2012) Coping with adverse drug events in patients with heart failure: Exploring
the role of medication beliefs and perceptions. Psychol Health 27: 570–587.
186. Ediger JP, Walker JR, Graff L, Lix L, Clara I, et al. (2007) Predictors of
medication adherence in inflammatory bowel disease. American Journal of
Gastroenterology 102: 1417–1426.
187. Emilsson M, Berndtsson I, Lotvall J, Millqvist E, Lundgren J, et al. (2011) The
influence of personality traits and beliefs about medicines on adherence to
asthma treatment. Prim Care Respir J 20: 141–147.
188. Fawzi W, Abdel Mohsen MY, Hashem AH, Moussa S, Coker E, et al. (2012)
Beliefs about medications predict adherence to antidepressants in older adults.
Int Psychogeriatr 24: 159–169.
189. Foo RC, Lamoureux EL, Wong RC, Ho SW, Chiang PP, et al. (2012)
Acceptance, attitudes, and beliefs of Singaporean Chinese toward an ocular
implant for glaucoma drug delivery. Invest Ophthalmol Vis Sci 53: 8240–8245.
190. Gauchet A, Tarquinio C, Fischer G (2007) Psychosocial predictors of
medication adherence among persons living with HIV. International Journal
of Behavioral Medicine 14: 141–150.
191. Gatti ME, Jacobson KL, Gazmararian JA, Schmotzer B, Kripalani S (2009)
Relationships between beliefs about medications and adherence. American
Journal of Health-System Pharmacy 66: 657–664.
192. George J, Shalansky SJ (2007) Predictors of refill non-adherence in patients
with heart failure. British Journal of Clinical Pharmacology 63: 488–493.
193. Griva K, Davenport A, Harrison M, Newman SP (2012) Non-adherence to
immunosuppressive medications in kidney transplantation: intent vs. forgetful-
ness and clinical markers of medication intake. Ann Behav Med 44: 85–93.
194. Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among
breast cancer patients taking tamoxifen. Patient Education & Counseling 59:
97–102.
195. Hedenrud T, Jonsson P, Linde M (2008) Beliefs about medicines and
adherence among Swedish migraineurs. Annals of Pharmacotherapy 42: 39–
45.
196. Horne R, Sumner S, Jubraj B, Weinman J, Frost S (2001) Haemodialysis
patients’ beliefs about treatment: Implications for adherence to medication and
fluid-diet restrictions. International Journal of Pharmacy Practice 9: 169–175.
197. Horne R, Buick D, Fisher M, Leake H, Cooper V, et al. (2004) Doubts about
necessity and concerns about adverse effects: Identifying the types of beliefs that
are associated with non-adherence to HAART. International Journal of STD
and AIDS 15: 38–44.
198. Horne R, Cooper V, Gellaitry G, Date HL, Fisher M (2007) Patients’
Perceptions of Highly Active Antiretroviral Therapy in Relation to Treatment
Uptake and Adherence: The Utility of the Necessity-Concerns Framework.
JAIDS 45: 334–341.
199. Hou R, Cleak V, Peveler R (2010) Do treatment and illness beliefs influence
adherence to medication in patients with bipolar affective disorder? A
preliminary cross-sectional study. Eur Psychiatry 25: 216–219.
200. Hunot VM, Horne R, Leese MN, Churchill RC (2007) A Cohort Study of
Adherence to Antidepressants in Primary Care: The Influence of Antidepres-
sant Concerns and Treatment Preferences. The Primary Care Companion to
The Journal of Clinical Psychiatry 9: 91–99.
201. Iihara N, Suzuki K, Kurosaki Y, Morita S, Hori K (2010) Factorial invariance
of a questionnaire assessing medication beliefs in Japanese non-adherent
groups. Pharm World Sci 32: 432–439.
202. Jo´nsdo´ttir H, Friis S, Horne R, Pettersen KI, Reikvam A˚, et al. (2009) Beliefs
about medications: measurement and relationship to adherence in patients with
severe mental disorders. Acta Psychiatrica Scandinavica 119: 78–84.
203. Kemp S, Feely M, Hay A, Wild H, Cooper C (2007) Psychological factors and
use of antiepileptic drugs: pilot work using an objective measure of adherence.
Psychology, Health & Medicine 12: 107–113.
204. Khanderia U, Townsend KA, Erickson SR, Vlasnik J, Prager RL, et al. (2008)
Medication adherence following coronary artery bypass graft surgery:
assessment of beliefs and attitudes. Annals of Pharmacotherapy 42: 192–199.
205. Kressin NR, Orner MB, Manze M, Glickman ME, Berlowitz D (2010)
Understanding contributors to racial disparities in blood pressure control. Circ
Cardiovasc Qual Outcomes 3: 173–180.
206. Kronish I, Diefenbach M, Edmondson D, Phillips LA, Fei K, et al. (2013) Key
Barriers to Medication Adherence in Survivors of Strokes and Transient
Ischemic Attacks. Journal of General Internal Medicine 28: 675–682.
207. Kung M, Koschwanez HE, Painter L, Honeyman V, Broadbent E (2012)
Immunosuppressant nonadherence in heart, liver, and lung transplant patients:
associations with medication beliefs and illness perceptions. Transplantation 93:
958–963.
208. Maguire LK, Hughes CM, McElnay JC (2008) Exploring the impact of
depressive symptoms and medication beliefs on medication adherence in
hypertension–A primary care study. Patient Education and Counseling 73:
371–376.
209. Mahler C, Hermann K, Horne R, Jank S, Haefeli WE, et al. (2012) Patients’
beliefs about medicines in a primary care setting in Germany. J Eval Clin Pract
18: 409–413.
210. Menckeberg TT, Bouvy ML, Bracke M, Kaptein AA, Leufkens HG, et al.
(2008) Beliefs about medicines predict refill adherence to inhaled corticoste-
roids. Journal of Psychosomatic Research 64: 47–54.
211. Moshkovska T, Stone M, Baker R, Smith R, Clatworthy J, et al. (2009) An
investigation of medication adherence to 5-aminosalicylic acid therapy in
patients with ulcerative colitis. Gut 58: A43–A44.
212. Nakhutina L, Gonzalez JS, Margolis SA, Spada A, Grant A (2011) Adherence
to antiepileptic drugs and beliefs about medication among predominantly
ethnic minority patients with epilepsy. Epilepsy Behav 22: 584–586.
213. Neame R, Hammond A (2005) Beliefs about medications: a questionnaire
survey of people with rheumatoid arthritis.[see comment]. Rheumatology 44:
762–767.
214. Nicklas LB, Dunbar M, Wild M (2010) Adherence to pharmacological
treatment of non-malignant chronic pain: the role of illness perceptions and
medication beliefs. Psychol Health 25: 601–615.
215. O’Carroll RE, McGregor LM, Swanson V, Masterton G, Hayes PC (2006)
Adherence to medication after liver transplantation in Scotland: a pilot study.
Liver Transplantation 12: 1862–1868.
216. Percival M, Cottrell WN, Jayasinghe R (2012) Exploring the beliefs of heart
failure patients towards their heart failure medicines and self care activities.
Int J Clin Pharm 34: 618–625.
Medication Adherence and Beliefs
PLOS ONE | www.plosone.org 23 December 2013 | Volume 8 | Issue 12 | e80633
217. Peters KF, Horne R, Kong F, Francomano CA, Biesecker BB (2001) Living
with Marfan syndrome II. Medication adherence and physical activity
modification. Clinical Genetics 60: 283–292.
218. Phatak HM, Thomas J 3rd (2006) Relationships between beliefs about
medications and nonadherence to prescribed chronic medications. Annals of
Pharmacotherapy 40: 1737–1742.
219. Rees G, Leong O, Crowston JG, Lamoureux EL (2010) Intentional and
unintentional nonadherence to ocular hypotensive treatment in patients with
glaucoma. Ophthalmology 117: 903–908.
220. Rees G, Chong XL, Cheung CY, Aung T, Friedman DS, et al. (2013) Beliefs
and Adherence to Glaucoma Treatment: A Comparison of Patients From
Diverse Cultures. J Glaucoma. doi: 10.1097/IJG.0b013e3182741f1c.
221. Reynolds K, Viswanathan HN, O’Malley CD, Muntner P, Harrison TN, et al.
(2012) Psychometric properties of the Osteoporosis-specific Morisky Medica-
tion Adherence Scale in postmenopausal women with osteoporosis newly
treated with bisphosphonates. Ann Pharmacother 46: 659–670.
222. Ruppar TM, Dobbels F, De Geest S (2012) Medication beliefs and
antihypertensive adherence among older adults: a pilot study. Geriatr Nurs
33: 89–95.
223. Russell J, Kazantzis N (2008) Medication beliefs and adherence to
antidepressants in primary care. The New Zealand medical journal 121: 14–
20.
224. Schoenthaler AM, Schwartz BS, Wood C, Stewart WF (2012) Patient and
physician factors associated with adherence to diabetes medications. Diabetes
Educ 38: 397–408.
225. Schuz B, Marx C, Wurm S, Warner LM, Ziegelmann JP, et al. (2011)
Medication beliefs predict medication adherence in older adults with multiple
illnesses. J Psychosom Res 70: 179–187.
226. Shiyanbola OO, Nelson J (2011) Illness perceptions, beliefs in medicine and
medication non-adherence among South Dakota minority women with
diabetes: a pilot study. S D Med 64: 365–368.
227. Sirey JA, Greenfield A, Weinberger MI, Bruce ML (2013) Medication beliefs
and self-reported adherence among community-dwelling older adults. Clin
Ther 35: 153–160.
228. Sofianou A, Martynenko M, Wolf MS, Wisnivesky JP, Krauskopf K, et al.
(2013) Asthma beliefs are associated with medication adherence in older
asthmatics. J Gen Intern Med 28: 67–73.
229. Tibaldi G, Clatworthy J, Torchio E, Argentero P, Munizza C, et al. (2009) The
utility of the Necessity–Concerns Framework in explaining treatment non-
adherence in four chronic illness groups in Italy. Chronic Illness 5: 129–133.
230. Treharne GJ, Lyons AC, Kitas GD (2004) Medication adherence in
rheumatoid arthritis: effects of psychosocial factors Psychology, Health and
Medicine 13: 337–349.
231. Uusku¨la A, Laisaar K-T, Raag M, Sˇmidt J, Semjonova S, et al. (2012)
Antiretroviral therapy (ART) adherence and correlates to nonadherence
among people on ART in Estonia. AIDS Care 24: 1470–1479.
232. van den Bemt BJF, van den Hoogen FHJ, Benraad B, Hekster YA, van Riel
PLCM, et al. (2009) Adherence Rates and Associations with Nonadherence in
Patients with Rheumatoid Arthritis Using Disease Modifying Antirheumatic
Drugs. The Journal of Rheumatology 36: 2164–2170.
233. Voils CI, Maciejewski ML, Hoyle RH, Reeve BB, Gallagher P, et al. (2012)
Initial validation of a self-report measure of the extent of and reasons for
medication nonadherence. Med Care 50: 1013–1019.
234. Wileman V, Chilcot J, Norton S, Hughes L, Wellsted D, et al. (2011) Choosing
not to take phosphate binders: the role of dialysis patients’ medication beliefs.
Nephron Clin Pract 119: c205–213.
235. Wong M, Mulherin D (2007) The influence of medication beliefs and other
psychosocial factors on early discontinuation of disease-modifying anti-
rheumatic drugs. Musculoskeletal Care 5: 148–159.
236. Yu ZL, Yeoh LY, Seow YY, Luo XC, Griva K (2012) Evaluation of adherence
and depression among patients on peritoneal dialysis. Singapore Med J 53:
474–480.
237. Zerah L, Arena C, Morin AS, Blanchon T, Cabane J, et al. (2012) [Patients’
beliefs about long-term glucocorticoid therapy and their association to
treatment adherence]. Rev Med Interne 33: 300–304.
Medication Adherence and Beliefs
PLOS ONE | www.plosone.org 24 December 2013 | Volume 8 | Issue 12 | e80633
